Trials / Completed
CompletedNCT00452673
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn about the safety and efficacy of Dasatinib in combination with Capecitabine for patients with advanced breast cancer, and who have received treatment with a taxane and an anthracycline
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib | Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression |
| DRUG | Capecitabine | Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression. |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2007-03-27
- Last updated
- 2015-03-24
- Results posted
- 2013-12-06
Locations
7 sites across 3 countries: United States, Italy, Spain
Source: ClinicalTrials.gov record NCT00452673. Inclusion in this directory is not an endorsement.